These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Advances in vertebrate aging research 2007. Austad S Aging Cell; 2008 Mar; 7(2):119-24. PubMed ID: 18221412 [TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288 [TBL] [Abstract][Full Text] [Related]
9. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity. Sharp ZD; Strong R J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):580-9. PubMed ID: 20083554 [No Abstract] [Full Text] [Related]
10. Mitochondrial redox metabolism: aging, longevity and dietary effects. Page MM; Robb EL; Salway KD; Stuart JA Mech Ageing Dev; 2010 Apr; 131(4):242-52. PubMed ID: 20219522 [TBL] [Abstract][Full Text] [Related]
11. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice. Koehl GE; Spitzner M; Ousingsawat J; Schreiber R; Geissler EK; Kunzelmann K Oncogene; 2010 Mar; 29(10):1553-60. PubMed ID: 19966863 [TBL] [Abstract][Full Text] [Related]
12. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Ji J; Zheng PS Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778 [TBL] [Abstract][Full Text] [Related]
13. Predicting whether dietary restriction would increase longevity in species not tested so far. Le Bourg E Ageing Res Rev; 2010 Jul; 9(3):289-97. PubMed ID: 20105461 [TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552 [TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? Rostaing L; Kamar N J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724 [TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin: a new target in prostate cancer. Rai JS; Henley MJ; Ratan HL Urol Oncol; 2010; 28(2):134-8. PubMed ID: 19523861 [TBL] [Abstract][Full Text] [Related]
17. The functional costs and benefits of dietary restriction in Drosophila. Burger JM; Hwangbo DS; Corby-Harris V; Promislow DE Aging Cell; 2007 Feb; 6(1):63-71. PubMed ID: 17266676 [TBL] [Abstract][Full Text] [Related]
18. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864 [TBL] [Abstract][Full Text] [Related]
19. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent. Curran KJ; Verheijen JC; Kaplan J; Richard DJ; Toral-Barza L; Hollander I; Lucas J; Ayral-Kaloustian S; Yu K; Zask A Bioorg Med Chem Lett; 2010 Feb; 20(4):1440-4. PubMed ID: 20089401 [TBL] [Abstract][Full Text] [Related]